on CureVac (NASDAQ:CVAC)
CureVac Announces Results of Extraordinary General Meeting
CureVac, a prominent biotech company, reported the outcomes of its Extraordinary General Meeting (EGM) held on November 25, 2025. Shareholders approved all proposals connected to BioNTech SE's public exchange offer for outstanding CureVac shares. The offer received an approval rate exceeding 99.16% of votes cast.
The exchange offer will conclude at 9:00 am ET on December 3, 2025, with shareholders encouraged to submit shares by 6:00 pm ET on December 2, 2025, due to operational timelines.
Key agenda approvals included a legal merger with CureVac Merger B.V., releasing directors from liability, and appointing new directors. Notably, the voting favoured the merger and appointments with a high percentage of affirmative votes.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news